Findings

What do systematic reviews say?

9 questions · 9 findings · 1 reviews · Colorectal

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 11.1%Low 1 · 11.1%Moderate 4 · 44.4%High 3 · 33.3%

Progression‐free survival · people with metastatic colorectal cancer ‐ KRAS exon 2 WT

The intervention leads to lower progression‐free survival (high certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.7 [0.6, 0.82]
12 studies · 4402 participants
High

Progression‐free survival · people with metastatic colorectal cancer ‐ extended RAS WT

The intervention probably leads to lower progression‐free survival (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.6 [0.48, 0.75]
6 studies · 1237 participants
Moderate

Progression‐free survival · people with metastatic colorectal cancer ‐ extended RAS MT

The intervention showed no clear difference in progression‐free survival (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.13 [0.93, 1.36]
6 studies · 2023 participants
Moderate

Progression‐free survival · people with metastatic colorectal cancer, not selected by KRAS status

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1483 participants
High

Progression‐free survival · people with metastatic colorectal cancer

The intervention showed no clear difference in progression‐free survival (high certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.02 [0.93, 1.12]
4 studies · 2189 participants
High

Progression‐free survival · people with metastatic colorectal cancer, not selected by KRAS status

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 1651 participants
Moderate

Progression‐free survival · people with metastatic colorectal cancer, not selected by KRAS status

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 181 participants
Low

Progression‐free survival · people with metastatic colorectal cancer

It is very uncertain whether the intervention changes progression‐free survival (very low certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.04 [0.83, 1.29]
6 studies · 1571 participants
Very low

Progression‐free survival · people with metastatic colorectal cancer ‐ KRAS exon 2 MT

The intervention showed no clear difference in progression‐free survival (moderate certainty).

1 finding from 1 review

Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.03 [0.89, 1.2]
8 studies · 2567 participants
Moderate